BioNTech vets raise about $90M in Series A for bispecific immunology research
A new immunology biotech closed its Series A, and it’s backed by investors intricately familiar with the industry. Bambusa Therapeutics said Friday that it raised “approximately” $90 million in the financing ...
A new immunology biotech closed its Series A, and it’s backed by investors intricately familiar with the industry.
Bambusa Therapeutics said Friday that it raised “approximately” $90 million in the financing ...
